Advancing Patient Survival in High Mortality Cancers

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

Partnership with Columbia University

We seek out high-quality scientific programs from the world’s top research institutions to translate years of pedigreed scientific research into potential therapeutics.

Our initial compound, ST-36, was discovered at Columbia University and has more than a decade of research supporting its development as an anti-cancer agent. As the exclusive licensee of certain patent applications and intellectual property owned by Columbia University, we intend to initially develop ST-36 for the treatment of GBM (an orphan oncology indication), with the potential to expand to various additional types of cancer.

Developing therapies that have synergistic or additive effects with existing therapies

Our strategy is to develop novel therapeutic agents that dramatically improve patient survival in high mortality cancers. We seek to develop therapies that have synergistic or additive effects with current therapies, and we intend to develop our drugs to be used in combination with other approved cancer treatments.

Elements of our strategy include:

  • Development of our lead product candidate, ST-36, in GBM, the most severe form of brain cancer, initially to improve response rates and progression-free survival in combination with existing standards of care
  • Assessment of the impact of ST-36 on additional tumor types
  • Evaluation of in-licensing opportunities that fit our oncology and high unmet need focus to potentially expand our pipeline

Science Backed by Strong Leadership

Our world-class team of executives and scientists are helping us pave the way to providing therapeutics for significant unmet medical needs.